These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16163434)

  • 21. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
    Gluhovschi G; Mateş A; Gluhovschi C; Golea O; Gădălean F; Somai M; Ene I; Petrica L; Velciov S
    Rom J Intern Med; 2014; 52(1):30-8. PubMed ID: 25000676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.
    Schepkens H; Vanholder R; Billiouw JM; Lameire N
    Am J Med; 2001 Apr; 110(6):438-41. PubMed ID: 11331054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence of hyperkalemia in high risk patients during treatment with an angiotensin converting enzyme inhibitor (Lisinopril) versus an angiotensin II receptor blocker (Losartan).
    Zanabli AR; Yango A; Dworkin L
    S D J Med; 2004 Jun; 57(6):227-31. PubMed ID: 15253477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
    Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.
    Solomon SD; Appelbaum E; Manning WJ; Verma A; Berglund T; Lukashevich V; Cherif Papst C; Smith BA; Dahlöf B;
    Circulation; 2009 Feb; 119(4):530-7. PubMed ID: 19153265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease.
    Preston RA; Afshartous D; Garg D; Medrano S; Alonso AB; Rodriguez R
    Hypertension; 2009 May; 53(5):754-60. PubMed ID: 19307466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort.
    Abbas S; Ihle P; Harder S; Schubert I
    Pharmacoepidemiol Drug Saf; 2015 Apr; 24(4):406-13. PubMed ID: 25683504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR; Rolfe M
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
    Surabenjawong U; Thunpiphat N; Chatsiricharoenkul S; Monsomboon A
    J Med Assoc Thai; 2013 Aug; 96(8):905-10. PubMed ID: 23991595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case of losartan induced angioedema.
    Nair C
    Indian J Med Sci; 2010 Feb; 64(2):81-4. PubMed ID: 22466497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
    Juurlink DN; Mamdani MM; Lee DS; Kopp A; Austin PC; Laupacis A; Redelmeier DA
    N Engl J Med; 2004 Aug; 351(6):543-51. PubMed ID: 15295047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Losartan-induced Stevens-Johnson syndrome in a geriatric patient].
    Bonnici H; Bygum A
    Ugeskr Laeger; 2007 Mar; 169(13):1233-4. PubMed ID: 17425932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic.
    Goland S; Naugolny V; Korbut Z; Rozen I; Caspi A; Malnick S
    Eur J Intern Med; 2011 Aug; 22(4):424-7. PubMed ID: 21767763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antihypertensive therapy and its effects on potassium homeostasis.
    Sica DA
    J Clin Hypertens (Greenwich); 2006 Jan; 8(1):67-73. PubMed ID: 16407694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist.
    Davis KL; Nappi JM
    Clin Ther; 2003 Nov; 25(11):2647-68. PubMed ID: 14693297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology.
    Chiu AG; Krowiak EJ; Deeb ZE
    Laryngoscope; 2001 Oct; 111(10):1729-31. PubMed ID: 11801934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.
    Gross E; Rothstein M; Dombek S; Juknis HI
    Am J Kidney Dis; 2005 Jul; 46(1):94-101. PubMed ID: 15983962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Losartan and hypertensive children. Another option for a small number of children.
    Prescrire Int; 2010 Aug; 19(108):160. PubMed ID: 20939445
    [No Abstract]   [Full Text] [Related]  

  • 39. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
    Fuster D; Frey FJ; Ferrari P
    Praxis (Bern 1994); 2000 Dec; 89(49):2073-6. PubMed ID: 11190849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Drug-related hyperkalemia resulted from spironolactone and angiotensin converting enzyme inhibitors therapy].
    Dutka M; Dzielski T; Wojciechowska J; Heller L; Trybus M
    Pol Merkur Lekarski; 1999 Aug; 7(38):69-70. PubMed ID: 10522422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.